[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ild\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ild":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,45,70,95,119,146,176,201,226,246,269],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100591664","validation-and-clinical-utility-of-the-lung-sliding-index-lsi-for-differentiating-pulmonary-diseases-100591664",false,"NCT06983366","Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases","Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases: A Prospective Case-Control Study","Inclusion Criteria:\n\n* Age 18 years and older.\n* Diagnosed with one of the specified pulmonary diseases, or a healthy control\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to tolerate or undergo a lung ultrasound\n* Extensive chest wall pathology precluding assessment\n* Unscorable \\>2 zones per protocol\n* Withdrawal of consent\n* Mechanically-ventilated patients",true,"ALL","18 Years",{"count":20,"type":21},700,"ESTIMATED","OBSERVATIONAL","This upcoming case-control study aims to confirm the Lung Sliding Index (LSI), a new ultrasound score that measures how well the pleura moves, in various lung diseases. The study will check how well the LSI can tell apart different lung diseases (like pneumothorax, interstitial lung disease, COPD, pneumonia, and pulmonary edema), how it relates to signs of disease severity, and how consistent the results are between different operators who have received the same training. Secondary objectives include assessing patient and operator satisfaction and feasibility using validated Likert scales.",[25,26,27,28,29,30,31],"COPD","ILD","Bronchiectasis","Pneumothorax","Pneumonia","Pleural Effusion Disorder","Pulmonary Oedema","RECRUITING","2026-04-26",{"date":35,"type":36},"2026-04-30","ACTUAL",{"date":38,"type":36},"2025-05-30",{"date":40,"type":21},"2026-08-01",{"name":42,"class":43},"Assiut University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100619466","effect-of-indoor-air-quality-improvement-on-health-in-patients-with-interstitial-lung-disease-100619466","NCT07344987","Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease","A Randomized Crossover Trial of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease","Inclusion Criteria:\n\n* Patients diagnosed with interstitial lung disease (ILD).\n* Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.\n\nExclusion Criteria:\n\n* Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders.\n* A history of respiratory tract infection within the past two weeks.","19 Years",{"count":54,"type":21},100,"INTERVENTIONAL",[57],"NA","Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.",[26],"NOT_YET_RECRUITING","2026-01-07",{"date":63,"type":36},"2026-01-15",{"date":65,"type":21},"2026-03",{"date":67,"type":21},"2027-06",{"name":69,"class":43},"Peking Union Medical College",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":55,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":44},"100445899","sputum-cytometry-guided-management-for-the-elimination-of-chronic-cough-in-patients-with-ild-100445899","NCT05086432","Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD","Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With Interstitial Lung Disease (SpECC-ILD) - a Randomized Controlled Trial","SpECC-ILD","Inclusion Criteria:\n\n* Written informed consent consistent with ICH-GCP and local laws, signed prior to any study procedures being performed\n* Age \\>18 years\n* A clinical diagnosis of ILD with accepted specific diagnoses including:\n* Idiopathic pulmonary fibrosis (IPF)\n* Chronic hypersensitivity pneumonitis associated ILD (CHP-ILD)\n* Connective tissue disease associated ILD (CTD-ILD)\n* Pneumoconiosis\n* Daily Cough for at least 8 weeks\n* Able to produce an adequate sample with sputum induction\n\nExclusion Criteria:\n\n* Patients with a diagnosis of systemic sclerosis associated ILD (SSc-ILD) or sarcoidosis\n* Cause of cough attributed to a known etiology (ex. ACE-inhibitor, uncontrolled gastroesophageal reflux or upper airway cough syndrome, acute viral illness)\n* Current use of inhaled corticosteroids\n* Current use of systemic corticosteroids (prednisone equivalent \\> 20mg\u002Fday)\n* Current use of chronic antibiotics\n* Airflow obstruction (ie. pre-bronchodilator FEV1\u002FFVC ratio \\\u003C 0.7)\n* History of physician-diagnosed asthma\n* History of emphysema\n* A history of cholestatic jaundice or hepatic dysfunction associated with prior use of azithromycin\n* Moderate to severe hepatic dysfunction with a Child Pugh score \\>10\n* Known allergy or hypersensitivity to inhaled corticosteroids or macrolide antibiotics\n* Corrected QT-interval (QTc) on screening electrocardiogram (ECG) of \\> 450ms\n* An established history of untreated atypical mycobacterial infection\n* A history of hearing impairment, tinnitus, or vertigo\n* Medication use likely to suppress cough (ex: morphine, gabapentin, amitriptyline)",{"count":79,"type":21},120,[57],"In Interstitial Lung Disease (ILD) there is thickening of lung tissue, which makes it difficult for patients to breathe and get enough oxygen into their bodies. In addition to shortness of breath, daily cough is very common, with 4 out of 5 patients experiencing this symptom. Cough in particular has a major impact on the ability to exercise, be active, and to simply enjoy life.\n\nThere are many reasons for cough in ILD, and very often there are multiple overlapping causes. It is hard to improve cough in these patients, with available medicines providing limited relief. One explanation for this gap is an incomplete understanding of cough in ILD. To improve patients' cough there is a need to better understand its cause. In other lung diseases, such as asthma, doctors and scientists have used phlegm tests to measure inflammation in the lung, which helps them choose the right medicine for the right patient. This has not been done for ILD, even though it has recently been found that many patients with ILD and everyday cough have abnormal phlegm tests. Using this strategy in ILD could improve patients' cough and quality of life, and possibly even slow progression of the disease.",[26],[26,84,85],"Sputum","Chronic cough","2025-09-24",{"date":88,"type":36},"2025-09-29",{"date":90,"type":36},"2025-05-22",{"date":92,"type":21},"2027-03",{"name":94,"class":43},"McMaster University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":105,"studyType":22,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":44},"100600830","sweep-shuttle-walking-test-for-exercise-evaluation-in-pulmonary-resection-100600830","NCT07102589","SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary Resection","Predictive Value of the Shuttle Walking Test for Postoperative Dyspnea in Chronic Respiratory Disease Patients Undergoing Lung Resection: A Prospective Observational Study","SWEEP","Inclusion Criteria:\n\n* \\- Age ≥ 40 years\n* Scheduled for surgical lung resection (e.g., for lung cancer or benign tumor)\n* Diagnosis of chronic respiratory disease (COPD, ILD, or bronchiectasis)\n* Able to perform Shuttle Walking Test (ISWT + ESWT) before surgery\n* Able to complete pre- and postoperative symptom questionnaires (dyspnea, EQ-5D)\n\nExclusion Criteria:\n\n* \\- Illiteracy or inability to read study materials\n* Inability to communicate in Korean\n* Decline or withdraw consent\n* Severe lower limb disability interfering with walking (e.g., fracture, paralysis)","40 Years",{"count":54,"type":21},"3 Months","This is a prospective observational study that evaluates whether the Shuttle Walking Test (SWT) can predict postoperative symptoms, particularly dyspnea, in patients with chronic respiratory diseases undergoing lung resection.\n\nCurrently, tools such as DLCO or cardiopulmonary exercise testing (CPET) are used to assess surgical risk and exercise capacity before lung surgery. However, these tests are not always accessible due to equipment limitations or long waiting times. The SWT is a simpler, safer, and more cost-effective alternative that has been recently recognized as a new medical technology in Korea for evaluating exercise capacity.\n\nIn this study, patients with chronic lung diseases (such as COPD, ILD, or bronchiectasis) who are scheduled to undergo lung resection will perform the SWT before surgery. Their symptoms and quality of life will be assessed through questionnaires before and three months after the surgery. The goal is to determine whether SWT results can help predict postoperative dyspnea and provide useful information for preoperative risk stratification.",[25,26,27,108,109],"Lung Cancer NOS","Dyspnea During Activity","2025-07-30",{"date":112,"type":36},"2025-08-04",{"date":114,"type":36},"2025-06-01",{"date":116,"type":21},"2026-05-31",{"name":118,"class":43},"Seoul National University Bundang Hospital",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":126,"conditions":127,"keywords":132,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":44},"100597560","the-use-of-entropy-to-assess-sleep-disordered-breathing-in-chronic-respiratory-disease-100597560","NCT07060079","The Use of Entropy to Assess Sleep Disordered Breathing in Chronic Respiratory Disease","Inclusion Criteria:\n\n* All adult patients (≥ 18years) with chronic respiratory disease with\u002Fwithout SDB.\n* patients who have had previously negative studies as a control group.\n* Subject is able to read, understand, and sign the informed consent form.\n* Willing to sleep with portable monitoring devices.\n\nExclusion Criteria:\n\n* Patients who are under 18 years of age at the time of the index study.\n* Contraindications to the use of portable monitoring.\n* Inability to give informed consent to take part in the study.",{"count":79,"type":21},"Research is being conducted into chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, and bronchiectasis. The investigation specifically focuses on sleep-disordered breathing (SDB) in individuals with chronic respiratory disease. SDB encompasses a range of conditions, the most common of which is obstructive sleep apnoea. In obstructive sleep apnoea, periodic pauses in breathing (apnoea) lead to reduced blood oxygen levels. To detect these events, patients typically undergo sleep studies that involve monitoring oxygen saturation, heart rate, and respiratory patterns during sleep. When chronic respiratory disease and SDB coexist, breathing disturbances during sleep may be exacerbated.\n\nTo identify SDB, sleep studies are commonly used to assess oxygen levels, heart rate, and breathing patterns. The objective of this research is to identify differences between patients with chronic respiratory diseases who have SDB and those who do not. This will be achieved by analysing sleep study data using a novel analytical approach. The aim is to determine whether this method can yield more detailed insights into the underlying pathophysiology of these conditions.",[128,27,26,25,129,130,131],"Bronchial Asthma","OSAHS","OSA","Obesity Hypoventilation Syndrome (OHS)",[133,26,134,135,25,136],"SDB","Entropy","bronchiectasis","asthma","2025-07-08",{"date":139,"type":36},"2025-07-11",{"date":141,"type":36},"2025-04-30",{"date":143,"type":21},"2026-09-30",{"name":145,"class":43},"University College, London",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":55,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100421383","a-non-pharmacological-cough-control-therapy-100421383","NCT04767074","A Non-pharmacological Cough Control Therapy","A Non-pharmacological Cough Control Therapy as an Adjuvant of Pulmonary Rehabilitation in People With Interstitial Lung Diseases and Chronic Cough - A Feasibility Study","Inclusion Criteria:\n\n* Individuals will be included if having confirmed diagnosis of any ILD by a physician (as per Canadian Thoracic Society's guideline for evaluating patients with fibrotic interstitial lung disease) and a chronic cough lasting more than 8 weeks in duration\n\nExclusion Criteria:\n\n* self-reports of moderate or large sputum production\n* effective or suspected exacerbation of the respiratory condition in the past month\n* upper respiratory tract infection in the past month\n* use of angiotensin-converting enzyme inhibitor medication\n* changes in the prescribed medication in the previous month\n* evidence of traction bronchiectasis in the HRCT\n* evidence of other medical conditions that prevent performance of an exercise training program\n* unable to read or speak in English \u002F unable to provide informed consent.","85 Years",{"count":155,"type":21},24,[57],"Coughing affects almost all individuals with ILD leading to physical, psychological and social distress and prevents individuals from performing their activities of daily living, working or socialising in public places. Unfortunately, there are no licensed medications available to treat chronic cough and the few drugs that have been tried resulted in little efficacy and significant side effects. Drug-free cough control interventions have shown promise in reducing the severity and impact of coughing on patients' lives but have not been tested in individuals with ILD. This study aims to explore the feasibility and effectiveness of a non-pharmacological cough control therapy, as an adjuvant of pulmonary rehabilitation, in patients with ILD and chronic cough (\\>8 weeks in duration).",[159,26,160,161],"Cough","Pulmonary Disease","Pulmonary Fibrosis",[159,26,163,164,165],"Pulmonary rehabilitation","chronic cough","non-pharmacological cough therapy","2025-03-28",{"date":168,"type":36},"2025-04-03",{"date":170,"type":36},"2020-09-01",{"date":172,"type":21},"2025-12",{"name":174,"class":43},"West Park Healthcare Centre",2,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":153,"enrollmentInfo":184,"targetDuration":4,"studyType":55,"phases":186,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":44},"100583894","impact-of-remote-vital-signs-monitoring-in-people-using-long-term-oxygen-therapy-100583894","NCT06882265","Impact of Remote Vital Signs Monitoring in People Using Long-term Oxygen Therapy","Impact of Remote Vital Signs Monitoring in People Using Long-term Oxygen Therapy : a Randomized Clinical Trial","ILD; COPD","Inclusion Criteria:\n\n* Patients with a clinical, radiological and\u002For anatomopathological diagnosis of COPD and ILD according to the 2020 ATS\u002FJRS\u002FALAT guidelines;\n* Age over 18 years;\n* Clinical stability (absence of exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks;\n* Patients who are on optimized drug therapy, including long-term home oxygen therapy (LTOT)\n* Have a smartphone compatible with the monitoring device;\n* Signing of the ICF to participate in the study.\n\nExclusion Criteria:\n\n* Presence of other concomitant lung diseases;\n* Myocardial infarction within four months prior to the start of the study, unstable angina or severe heart disease (NYHA functional class III-IV) and\u002For decompensated.\n* Patients who received a lung transplant during the study\n* Living outside the coverage area or moving out of state",{"count":185,"type":21},60,[57],"Assess quality of life of patients using prolonged oxygen therapy",[26,25],[190,191,26,25],"Quality of life","Monitoring remote","2025-03-11",{"date":194,"type":36},"2025-03-18",{"date":196,"type":36},"2024-11-10",{"date":198,"type":21},"2025-12-15",{"name":200,"class":43},"University of Sao Paulo General Hospital",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":55,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100563508","benefit-of-high-flow-nasal-cannula-on-persistent-dyspnea-in-ild-100563508","NCT06617078","Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Ild","Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Interstitial Lung Disease: Randomized Multicentric Cross-over Trial","HIGHOXFILD","Inclusion Criteria:\n\n* Intertitial lung disease\n* Persistant dyspnea (mMRC≥3)\n* Long-term oxygen therapy at least for 3 months\n\nExclusion Criteria:\n\n* Chronic respiratory disease (COPD, lung cancer)\n* Pneumothorax,\n* Pneumomediastinum,\n* Active smoker,\n* Patient on non-invasive ventilation or continuous positive airway pressure (CPAP),\n* Pregnancy or breastfeeding,\n* Unable to read or understand questionnaires,\n* No written consent,\n* Patients under guardianship,\n* No health assurance coverage",{"count":210,"type":21},42,[57],"The main purpose of this study is to evaluate the effects of high-flow nasal therapy (HFNT) oxygen compared to long-term oxygen therapy (LTOT) on dyspnea and quality of life in intersititial lung disease patients with chronic respiratory failure and persistent breathlessness in whom LTOT has already been initiated.",[26],[215,26,216],"Chronic breathlessness","high nasal flow canula","2024-09-26",{"date":219,"type":36},"2024-09-27",{"date":221,"type":21},"2024-10-15",{"date":223,"type":21},"2026-10-15",{"name":225,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100554797","ild-in-obese-patients-with-osa-100554797","NCT06503757","ILD In Obese Patients With OSA","Misinterpretation of ILD In Obese Patients With OSA","Inclusion Criteria:\n\n* Presence of obesity, defined by body mass index (BMI) ≥30 kg\u002Fm².\n* Confirmed diagnosis of OSA based on polysomnography\n* Availability of HRCT scans for analysis\n\nExclusion Criteria:\n\n* OSA in non obese patients\n* History of lung surgery or lung transplantation.","70 Years",{"count":235,"type":21},94,"Assess the impact of obesity and OSA on the interpretation of high-resolution computed tomography (HRCT) findings in patients with ILD.\n\nIdentify specific challenges or confounding factors that may contribute to the misinterpretation of HRCT findings in this population.\n\nEvaluate the potential consequences of misinterpretation, including delayed or inaccurate diagnosis, inappropriate treatment decisions, and suboptimal patient outcomes.",[26],"2024-07-10",{"date":240,"type":36},"2024-07-16",{"date":242,"type":21},"2024-07-20",{"date":244,"type":21},"2025-01-20",{"name":42,"class":43},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":253,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":44},"100537639","sarcopenia-in-chronic-lung-diseases-100537639","NCT06280443","Sarcopenia in Chronic Lung Diseases","Epidemiological Study of Sarcopenia in Patients With Chronic Lung Diseases: A Prospective Registry Cohort Study","Inclusion Criteria:\n\n1. Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment.\n2. Those who meet the conditions for frailty diagnosis after assessment by the Frailty Scale\n3. Patients who agree to provide the ID card number to the research team for usage as a link to the National Health Insurance research database and Health bank to explore the continuity of care and the use of medical resources\n4. Age\\>=20\n\nExclusion Criteria:\n\n1. Patients who refuse to sign the consent form\n2. Patients who are bed ridden or unable to walk due to physical disabilities\n3. Patients with terminal cancer or human acquired immunodeficiency syndrome\n4. Patients with edema (pitting edema +2)","20 Years",{"count":255,"type":21},300,"Inclusion criteria A)Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment.\n\nB) Patients who agree to provide the ID card number to the research team for usage as a link to the National Health Insurance research database and Health bank to explore the continuity of care and the use of medical resources",[258,25,259,26],"Sarcopenia","Asthma","2024-04-02",{"date":262,"type":36},"2024-04-04",{"date":264,"type":36},"2022-11-25",{"date":266,"type":21},"2032-09-30",{"name":268,"class":43},"Taichung Veterans General Hospital",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":55,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":44},"100510459","evaluate-the-effect-of-dietary-supplement-combined-exercise-among-patients-with-sarcopenia-comorbid-with-lung-disease-100510459","NCT05926713","Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease","Evaluate the Effect of Dietary Supplement Combined Supervised Exercise on Physical Performance and Body Composition Among Patients With Sarcopenia and Severe Sarcopenia Comorbid With COPD or ILD: A Prospective, Multi-center Cohort Study","Inclusion Criteria:\n\n* Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from Department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment.\n* Outpatients who meet the diagnostic criteria for Sarcopenia after evaluation by a physician.\n\nExclusion Criteria:\n\n* Patients who refuse to sign the consent form\n* Patients who are under 20 years old\n* Patients who are bedridden or unable to walk due to physical disabilities\n* Patients with terminal cancer or human-acquired immunodeficiency syndrome\n* Patients with edema (grading pitting edema +2)",{"count":54,"type":21},[57],"This trial is a prospective multi-center study. The purpose of this study is to evaluate the effect of dietary supplement combined with supervised exercised on the physical performance, body composition and lung function among patients with Sarcopenia and severe Sarcopenia in chronic lung disease. After participants enroll in this study, 12-week clinical trial will be conducted to analyze the improvement regarding Sarcopenia and different severity of Sarcopenia before and after the intervention of exercise and nutritional products, which can further provide reference for clinical intervention and rehabilitation.",[258,25,26],"2023-06-21",{"date":282,"type":36},"2023-07-03",{"date":284,"type":36},"2023-03-01",{"date":286,"type":21},"2032-10-31",{"name":288,"class":289},"Orient Europharma Co., Ltd.","INDUSTRY"]